Cambrex

After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. 

Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.

East Rutherford, NJ – May 31, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.

Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.

Throughout CPHI North America (Philadelphia, PA; April 25–27, 2023), we caught up with some of the exhibiting organisations to ask what the show brings to the North American pharmaceutical sector, and what is driving industry innovation in this region of the world.    

Cambrex is a leading global CDMO that provides drug substance development and manufacturing across the entire drug lifecycle.

East Rutherford, NJ – May 16, 2023 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the second phase of its 51,000 square-foot expansion in Waltham, Massachusetts.

Analytical Services that Accelerate Drug Development and Commercialization

Our Science-Forward Approach to API Development and Manufacturing